610 related articles for article (PubMed ID: 28711086)
21. [New treatment options for metastatic melanoma].
Tietze JK; Berking C
Dtsch Med Wochenschr; 2014 Jul; 139(28-29):1462-7. PubMed ID: 24983194
[No Abstract] [Full Text] [Related]
22. Strides in melanoma announced: maximizing value comes next.
Tuma RS
J Natl Cancer Inst; 2011 Jul; 103(13):997-9. PubMed ID: 21693727
[No Abstract] [Full Text] [Related]
23. Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.
Samlowski W; Adajar C
BMC Cancer; 2021 Nov; 21(1):1187. PubMed ID: 34743688
[TBL] [Abstract][Full Text] [Related]
24. The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy.
Akabane H; Sullivan RJ
Am J Clin Dermatol; 2016 Feb; 17(1):1-10. PubMed ID: 26518880
[TBL] [Abstract][Full Text] [Related]
25. Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma.
Sengul Samanci N; Çelik E; Bagcilar O; Erol BC; Bicki E; Oruc K; Bedir S; Degerli E; Derin S; Demirci NS; Demirelli FH
Melanoma Res; 2020 Oct; 30(5):477-483. PubMed ID: 32898388
[TBL] [Abstract][Full Text] [Related]
26. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
27. Dabrafenib plus trametinib in BRAF K601E-mutant melanoma.
Rogiers A; Thomas D; Vander Borght S; van den Oord JJ; Bechter O; Dewaele M; Rambow F; Marine JC; Wolter P
Br J Dermatol; 2019 Feb; 180(2):421-422. PubMed ID: 30248172
[No Abstract] [Full Text] [Related]
28. Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.
Parakh S; Murphy C; Lau D; Cebon JS; Andrews MC
J Clin Pharm Ther; 2015 Feb; 40(1):121-3. PubMed ID: 25382067
[TBL] [Abstract][Full Text] [Related]
29. Potassium iodide in successful treatment of erythema nodosum-like lesions induced by combination therapy with dabrafenib and trametinib.
Sawada H; Kanehisa F; Katoh N; Asai J
J Dermatol; 2020 Jan; 47(1):e7-e8. PubMed ID: 31587335
[No Abstract] [Full Text] [Related]
30. A case of multi-metastatic melanoma with RAF1 fusion: a surprising response to anti-MEK therapy.
Pacaud A; Amintas S; Boussemart L; Cappellen D; Gérard E
Eur J Cancer; 2021 Apr; 147():161-163. PubMed ID: 33684875
[No Abstract] [Full Text] [Related]
31. Evolution of melanocytic nevi under vemurafenib, followed by combination therapy with dabrafenib and trametinib for metastatic melanoma.
Giurcaneanu C; Nitipir C; Popa LG; Forsea AM; Popescu I; Bumbacea RS
Acta Dermatovenerol Croat; 2015; 23(2):114-21. PubMed ID: 26228819
[TBL] [Abstract][Full Text] [Related]
32. Vemurafenib/dabrafenib and trametinib.
Rissmann R; Hessel MH; Cohen AF
Br J Clin Pharmacol; 2015 Oct; 80(4):765-7. PubMed ID: 25847075
[No Abstract] [Full Text] [Related]
33. Sweet syndrome in metastatic melanoma during treatment with dabrafenib and trametinib.
Scarfì F; Melotti B; Veronesi G; Ravaioli GM; Baraldi C; Lambertini M; Patrizi A; Dika E
Australas J Dermatol; 2019 Aug; 60(3):e242-e243. PubMed ID: 30724336
[No Abstract] [Full Text] [Related]
34. Myasthenia gravis following dabrafenib and trametinib for metastatic melanoma.
Zaloum A; Falet JR; Elkrief A; Chalk C
Neurology; 2020 Feb; 94(7):322-323. PubMed ID: 31888971
[No Abstract] [Full Text] [Related]
35. Targeted therapies for cutaneous melanoma.
Kee D; McArthur G
Hematol Oncol Clin North Am; 2014 Jun; 28(3):491-505. PubMed ID: 24880943
[TBL] [Abstract][Full Text] [Related]
36. Custo-utilidade de terapias-alvo comparadas à dacarbazina para o tratamento de primeira linha do melanoma avançado não-cirúrgico e metastático no Sistema Único de Saúde do Brazil.
Guerra RL; Corrêa FM; Fernandes RRA; Zimmerman IR
Value Health Reg Issues; 2019 Dec; 20():103-109. PubMed ID: 31174179
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant Therapy of Melanoma.
Tarhini AA
Hematol Oncol Clin North Am; 2021 Feb; 35(1):73-84. PubMed ID: 33759774
[TBL] [Abstract][Full Text] [Related]
38. Vemurafenib for the treatment of BRAF mutant metastatic melanoma.
Martin-Liberal J; Larkin J
Future Oncol; 2015; 11(4):579-89. PubMed ID: 25686114
[TBL] [Abstract][Full Text] [Related]
39. [Systemic treatment of melanoma brain metastases].
Le Rhun É; Mateus C; Mortier L; Dhermain F; Guillot B; Grob JJ; Lebbe C; Thomas M; Jouary T; Leccia MT; Robert C
Cancer Radiother; 2015 Feb; 19(1):48-54. PubMed ID: 25656856
[TBL] [Abstract][Full Text] [Related]
40. Resistance to BRAF-targeted therapy in melanoma.
Sullivan RJ; Flaherty KT
Eur J Cancer; 2013 Apr; 49(6):1297-304. PubMed ID: 23290787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]